Moderna ETFs To Gain On New Positive COVID-19 Vaccine Data

The first company to start human clinical trials of its coronavirus vaccine candidate in the United States — Moderna MRNA — has once again come up with encouraging study data relating to mRNA-1273. Per the latest data from an early stage clinical trial, its experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults similar to those observed in younger participants.

Moderna experimented its vaccine on 10 adults between the ages of 56 and 70 and 10 elderly adults aged 71 and older, according to a CNBC article. Each participant was administered two 100 microgram doses of the vaccine 28 days apart. Following the announcement of the positive data, Moderna’s shares rose around 6.42% in yesterday’s trading session.

Notably, Moderna recently signed a $1.5-billion coronavirus vaccine supply agreement with the U.S. government. The contract has been entered into for the manufacturing and delivery of initial 100 million doses of its potential coronavirus vaccine, mRNA-1273, with the price coming in at nearly $30.50 per person for a two-dose course of treatment (per a Reuters article).

The agreement with Moderna also includes incentive payments for timely delivery of the product. It also states that the U.S. government has an option to purchase up to an additional 400 million doses of the potential coronavirus vaccine from Moderna. Also, going by a Reuters article, Moderna has received nearly $1 billion in funding from the U.S. government under its Operation Warp Speed program.

Moderna’s Journey So Far

Moderna, which is developing this vaccine in collaboration with the National Institute of Allergy and Infectious Diseases, has begun the Phase 3 clinical trial, encompassing 30,000 healthy participants at around 100 research sites in the United States.

The participants in the trial will be given either two 100 microgram doses of the vaccine or a placebo in a gap of around 28 days. Moreover, participants and investigators will not be informed about who has received the vaccine.

1 2 3
View single page >> |

Disclosure: contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any specific ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
William K. 1 year ago Member's comment

Clearly some parts of health care will be very lucrative for a while.

And now a comment about that testing on 30,000 humans. while 15,000 will receive a vaccine that has demonstrated the ability to prevent the virus infection, the other 15,000 will be lied to and given a fake vaccine providing no benefit whatsoever. I see that as a rather nasty act of cruelty. Of course there is the claim that it is needed to prove the benefits, and that it is just "good science," but I equate it to tha Nazi guards "just doing their duty" at the extermination camps. In this case it is lives intentionally being placed at severe risk, quite intentionally.